BioMAdvanced Diagnostics
Frederic Pette has had a diverse and impressive career spanning over two decades. Frederic'smost recent role is as the Co-founder and CEO of BioMAdvanced Diagnostics, a biotech/medtech startup based in Nantes. The company focuses on developing companion molecular diagnostic tests and biomarkers that target patients' immune responses. Prior to this, Frederic co-founded and served as the Lead Partner of AGFPR Holding.
Frederic has also held various positions at Getinge, a global medical technology company. Frederic served as the Executive VP of Corporate Business Development and later as the Acting President of Surgical Workflows. During their tenure, they achieved above-market growth in sales and successfully reactivated existing partnerships while initiating new strategic ones.
Before joining Getinge, Frederic worked at Maquet Getinge Group, where they were the President of the Division Surgical Workplaces and later the VP of France. In these roles, they oversaw general management, including R&D, supply chain, marketing, sales, and compliance. Frederic was instrumental in doubling commercial growth and driving sales expansion.
Prior to Maquet Getinge Group, Frederic served as the Country Manager at AMS France, a global leader in urology and gynecology. Frederic consistently achieved above-market growth, leading the department to a 10% CAGR during their tenure.
Frederic's career began at Stryker, a renowned medical technology company. Frederic held positions as the Franchise Manager and Product Manager for Hips in the EMEA region. Frederic played a crucial role in transforming market segmentation and successfully led international product launches.
Before the medical technology industry, Frederic worked at Zimmer, a trusted brand for bone and joint healthcare solutions. Frederic served as the Marketing Manager and Product Manager for Hips in France. Frederic executed a strategic plan that resulted in significant sales growth and orchestrated a groundbreaking PR campaign that earned recognition within the industry.
At the start of their career, Frederic worked as the International HR Manager at Barilla, where they gained valuable experience in human resources management. Frederic also held the position of Attaché Sectoriel at Poste d'Expansion Economique in Rome, Italy.
Overall, Frederic Pette's work experience showcases their expertise in the medical technology and biotech industries, their ability to drive growth and achieve exceptional results, and their leadership in various management roles.
Frederic Pette completed their MBA in General Management from UCLA Anderson School of Management, between the years 2000 and 2002. Prior to that, they pursued a DESS degree in Management des Ressources Humaines at the University of Lille 1 Sciences and Technology, from 1995 to 1996. Frederic had also completed a Maîtrise en Sciences Economiques in Economics at the same university in the academic year 1994-1995. Before that, they obtained a Licence en Sciences Economiques, specializing in Economics, from the University of Lille 1 Sciences and Technology for the academic year 1993-1994.
This person is not in any teams
BioMAdvanced Diagnostics
BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes. BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers related to the Immune System based on 20 years of translational research. Its main goal is to enable a really personalized medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians. More specifically, great attention is being placed towards diminishing risks for patients through minimal invasive solutions which will enable very substantial cost reductions for the Health Systems. The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. The identification of biomarkers to evaluate, predict and diagnose the risk of transplant rejection will provide clinicians with ways of better anticipating and adapting their patients’ treatment. The goal being to reduce as much as possible numerous secondary effects. BioMAdvanced Diagnostics Tests will provide predictive scores and will be easily integrated into diagnostic and standard treatment protocols, easy to use by medical practitioners. BioMAdvanced Diagnostics is incubated by Atlanpole and supported by SATT Ouest Valorisation. In September 2022, the company announced a round of seed investment, raising 1,7 million euros.